Regulatory
United States — Food and Drug Administration: The FDA issued the Complete Response Letter for Unicycive's resubmitted NDA for oxylanthanum carbonate, citing the same third-party manufacturing deficiencies as the prior June 2025 CRL, which triggered the stock decline and the lawsuits.
Unicycive Therapeutics: Unicycive is the defendant and central subject of the securities fraud class action, facing allegations of misleading investors about third-party manufacturing deficiencies and the resulting FDA Complete Response Letter for oxylanthanum carbonate. The stock reportedly fell 39.1% on the CRL disclosure, and the litigation adds legal costs and reputational damage.
Sep 03, 2026 · 58 articles